Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025)

Avalo Therapeutics' EBT Margin history spans 12 years, with the latest figure at 23033.9% for Q4 2025.

  • For Q4 2025, EBT Margin fell 468754.0% year-over-year to 23033.9%; the TTM value through Dec 2025 reached 132362.71%, down 12442280.0%, while the annual FY2025 figure was 132362.71%, 12442280.0% down from the prior year.
  • EBT Margin reached 23033.9% in Q4 2025 per AVTX's latest filing, down from 18346.35% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 9246.18% in Q3 2024 to a low of 23033.9% in Q4 2025.
  • Average EBT Margin over 5 years is 4024.64%, with a median of 1432.05% recorded in 2023.
  • The largest YoY upside for EBT Margin was 1145805bps in 2024 against a maximum downside of -1691431bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 8742.92% in 2021, then skyrocketed by 87bps to 1094.2% in 2022, then crashed by -31bps to 1432.05% in 2023, then tumbled by -1181bps to 18346.35% in 2024, then fell by -26bps to 23033.9% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's EBT Margin are 23033.9% (Q4 2025), 18346.35% (Q4 2024), and 9246.18% (Q3 2024).